Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Angiomotin‐like 1 plays a tumor‐promoting role in glioma by enhancing the activation of YAP1 signaling
Angiomotin‐like 1 (AMOTL1) is reportedly a pivotal tumor‐associated protein that is strongly associated with the tumorigenesis of multiple malignant tumors. However, the issue of whether AMOTL1 plays a role in the tumorigenesis of glioma remains unclear. The aim of this work was to explore the possible relationship between AMOTL1 and glioma progression. Results demonstrated that high levels of AMOTL1 in glioma tissues were associated with a reduced survival rate in patients with glioma. Cellular functional assays revealed that silencing of AMOTL1 in glioma cell lines substantially decreased cell proliferation and invasion and increased cell apoptosis. Further investigation revealed that silencing of AMOTL1 inhibited the activation of yes‐associated protein 1 (YAP1) and decreased the expression of YAP1 target genes. Reactivation of YAP1 reversed AMOTL1‐silencing‐induced antitumor effects, whereas inhibition of YAP1 abolished AMOTL1‐overexpression‐induced tumor‐promoting effects in glioma cells. Silencing of AMOTL1 also retarded the growth of glioma cell‐derived xenograft tumors in vivo. In conclusion, these findings suggested that AMOTL1 may exert a tumor‐promoting function in glioma by enhancing the activation of YAP1 signaling. This work suggested AMOTL1 as a potential target for the development of antiglioma therapy.
Angiomotin‐like 1 plays a tumor‐promoting role in glioma by enhancing the activation of YAP1 signaling
Angiomotin‐like 1 (AMOTL1) is reportedly a pivotal tumor‐associated protein that is strongly associated with the tumorigenesis of multiple malignant tumors. However, the issue of whether AMOTL1 plays a role in the tumorigenesis of glioma remains unclear. The aim of this work was to explore the possible relationship between AMOTL1 and glioma progression. Results demonstrated that high levels of AMOTL1 in glioma tissues were associated with a reduced survival rate in patients with glioma. Cellular functional assays revealed that silencing of AMOTL1 in glioma cell lines substantially decreased cell proliferation and invasion and increased cell apoptosis. Further investigation revealed that silencing of AMOTL1 inhibited the activation of yes‐associated protein 1 (YAP1) and decreased the expression of YAP1 target genes. Reactivation of YAP1 reversed AMOTL1‐silencing‐induced antitumor effects, whereas inhibition of YAP1 abolished AMOTL1‐overexpression‐induced tumor‐promoting effects in glioma cells. Silencing of AMOTL1 also retarded the growth of glioma cell‐derived xenograft tumors in vivo. In conclusion, these findings suggested that AMOTL1 may exert a tumor‐promoting function in glioma by enhancing the activation of YAP1 signaling. This work suggested AMOTL1 as a potential target for the development of antiglioma therapy.
Angiomotin‐like 1 plays a tumor‐promoting role in glioma by enhancing the activation of YAP1 signaling
Xu, Gang (Autor:in) / Seng, Zhiyuan (Autor:in) / Zhang, Ming (Autor:in) / Qu, Jianqiang (Autor:in)
Environmental Toxicology ; 36 ; 2500-2511
01.12.2021
12 pages
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation
| Wiley | 2024
Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer
| Wiley | 2020
CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation
| Wiley | 2024
| Wiley | 2024